Leverage, Debt Maturities & Coverage
- Debt Profile: Elevance carries a significant debt load, but it’s manageable relative to its size. Total debt stood at $31.8 billion as of Q1 2026 (companiesmarketcap.com), against $44 billion in shareholders’ equity (www.businesswire.com). The debt-to-capital ratio is ~42%, well within the company’s debt covenants (max 60%) and consistent with prior periods (app.edgar.tools). Much of this debt is long-term senior notes issued at fixed rates.
- Maturity Schedule: Near-term refinancing needs are limited. Only about $1.1 billion of principal comes due in 2026, followed by $1.625 billion in 2027 (app.edgar.tools). Elevance has staggered its maturities thereafter – e.g. ~$2.0B in 2028 and $1.85B in 2030 – with fully $24 billion maturing beyond 2030 (app.edgar.tools). The company even refinanced some 2025–2026 notes with new longer-dated issuances last year (app.edgar.tools). This laddered debt structure and proactive refinancing help reduce rollover risk.
- Liquidity & Credit Facilities: The balance sheet shows solid liquidity. Cash and investments at the parent were about $2.2 billion at Q1’s end (www.elevancehealth.com). Elevance also maintains substantial borrowing capacity – a $5 billion revolving credit facility (undrawn, extended to 2030) (app.edgar.tools) (app.edgar.tools) and a $5 billion commercial paper program (also unused as of year-end 2025) (app.edgar.tools). These backstops provide flexibility to handle any short-term funding needs or opportunistic moves (e.g. funding acquisitions or buybacks) without straining cash.
- Interest Coverage: Despite rising interest rates, interest obligations are well-covered by earnings. Interest expense was $1.4 billion in 2025, up ~18% YoY as debt grew and rates climbed (www.sec.gov). Even so, operating profit comfortably exceeded interest costs – roughly 5× coverage based on 2025 operating earnings (~$7+ billion) versus interest. In Q1 2026, interest expense would represent an even smaller slice of operating income given stronger results. The company’s fixed-rate debt mix also shields it from immediate rate hikes (only short-term FHLB borrowings carry floating rates ~3.8% (app.edgar.tools)). Overall, Elevance’s leverage and interest burden appear moderate and sustainable for its A-rated credit profile.
Earnings Multiples & Valuation
- P/E and Growth Outlook: Elevance shares trade at a reasonable valuation after last year’s decline. Based on the current ~$90 billion market cap and management’s 2026 EPS guidance (~$26.75) (www.elevancehealth.com), the forward P/E is around 15×. This is below the broader market and in line with peers, given the company’s mid-teens earnings growth outlook. For context, Elevance’s trailing P/E (past 12 months) is ~17.6 (companiesmarketcap.com), elevated by one-time charges, while its FY2025 P/E was only ~13.9 (companiesmarketcap.com) after a drop in the share price. The stock’s multiple compressed in 2024–2025 amid cost headwinds, but may expand again if earnings reaccelerate. Management has expressed confidence in returning to a ≥12% EPS growth trajectory by 2027 (www.elevancehealth.com), which could support a higher valuation in the long run if achieved.
- Peer Comparison: Within the managed care sector, Elevance tends to trade at a slight discount to industry leader UnitedHealth Group on earnings multiples, reflecting its smaller scale and recent bumps in performance. For example, UNH often commanded high-teens P/Es during stable periods, whereas Elevance lingered in the low-to-mid teens. That gap could narrow if Elevance demonstrates improved consistency. Additionally, price-to-sales for ELV is around ~0.45× (using ~$200B revenue), similar to peers, while its dividend yield (~1.7%) is roughly on par with other big insurers (UnitedHealth ~1.5%, Cigna ~2% currently). In short, Elevance’s valuation appears undemanding relative to fundamentals – any clear uptick in execution or outlook could prompt re-rating closer to peer averages.
- Stock Performance: After hitting an all-time high of $567 in late 2024 (apnews.com), ELV shares suffered a sharp pullback on earnings disappointments and policy fears. The stock bottomed out near the low-$300s earlier this year amid sector-wide weakness. It has since rebounded to around $400–$420 per share (companiesmarketcap.com) following improved results and relief on Medicare rates. Year-to-date in 2026, Elevance has outperformed the broader market, but it still trails its historical highs. The relatively low valuation, ongoing buybacks, and stabilizing earnings could limit downside from here. However, sustained upside likely hinges on the company proving that the worst of the cost pressures are over (see Risks & Outlook below).
Risks & Red Flags
Elevance faces several risk factors and headwinds that investors should monitor:
- Medical Cost Pressures (Medicaid): A key concern is rising healthcare costs in government programs, especially Medicaid. In late 2024, Elevance was forced to cut its earnings forecast (from $37.20 to ~$33 per share) after a spike in Medicaid costs hit margins (apnews.com). Medicaid enrollment shrank by 19% (to ~8.9 million) in Q3 2024 as states removed pandemic-era enrollees, leaving a sicker mix of members that drove up claims (apnews.com). Because states set reimbursement using older data, Medicaid rates lagged behind the higher costs (apnews.com). This dynamic severely hurt profitability in 2H 2024. While Elevance has repriced or exited some unprofitable contracts, Medicaid remains a challenging segment. If medical utilization or cost trends exceed assumptions in 2026, margin erosion could recur. Investors will want to see signs that Medicaid cost ratios are stabilizing (or that states are adjusting payments appropriately).
- Medicare Advantage & Regulatory Policy: Medicare Advantage (MA) is another critical business facing policy volatility. In early 2026, the CMS (under the current administration) shocked the market with a proposal for essentially flat 2027 MA reimbursement (+0.09%), which hammered health insurer stocks (Elevance fell ~11% on that news) (www.axios.com). Although regulators later reversed course – announcing a 2.5% payment increase for 2027 (adding $13B industry-wide) (www.axios.com) – the episode highlights the political risk around government payments. MA has been a growth engine for Elevance (over 2 million MA members) (apnews.com), but margin pressure is a concern if funding doesn’t keep up with medical cost inflation. Furthermore, ongoing audits and rule changes to MA (e.g. risk adjustment, prior authorization rules) could pose earnings headwinds. The company and industry are actively lobbying for adequate rates, but this will remain a wild card, especially heading into an election year that could bring new healthcare policies.
- One-Time Charges & Regulatory Uncertainty: Elevance took a $935 million accrual in Q1 2026 for a “CMS notice” related matter (www.elevancehealth.com). While details are limited, this likely pertains to a regulatory or compliance issue (possibly a dispute over Medicare or Medicaid payments). Such a large charge underscores regulatory risk. An open question is whether this accrual will fully cover the exposure or if additional losses could emerge. Until the CMS matter is resolved, there’s an overhang of uncertainty. Additionally, the company incurred a $129 million restructuring charge in Q1 (www.elevancehealth.com) as it streamlines operations. Investors generally view cost-cutting positively, but there is always execution risk in restructuring initiatives. Success in reducing overhead could boost future earnings; failure could mean more charges or disruption.
- Competitive & Execution Risks: As a Blue Cross Blue Shield licensee in many states, Elevance operates in highly competitive markets. It faces intense competition from other national insurers (UnitedHealth, Humana, CVS/Aetna, Cigna) as well as regional players for employer plans, individual exchange enrollees, and Medicare members (www.elevancehealth.com). Winning and retaining contracts can pressure pricing. Elevance deliberately shed some employer and MA membership recently to focus on margin (“repositioning for sustainable performance” (www.elevancehealth.com)), which is a sound strategy but ceding market share could hurt scale advantages. There is a risk that aggressive competitors undercut rates or capture disenrolled members, making it harder for Elevance to re-grow membership later. Additionally, integration of past acquisitions and new business lines (e.g. Carelon services and pharmacy benefit operations) must deliver expected synergies. The company carries $39+ billion of goodwill and intangibles on its balance sheet (www.businesswire.com); if acquisitions underperform, impairment charges or write-downs could result (www.elevancehealth.com). So far, management remains confident, but it’s an area to watch.
- Macro Factors – Interest and Investments: With over $30 billion in debt, Elevance is exposed to interest rate risk. Rising rates have already increased interest expense (up >18% in 2025) (www.sec.gov). While most debt is fixed-rate, any future refinancing will come at higher yields, and floating-rate borrowings (like FHLB loans) become costlier. Higher interest costs could modestly weigh on earnings and cash flow if rates stay elevated. On the flip side, the company’s investment portfolio (insurance float invested in bonds/equities) can be volatile – in Q1, Elevance actually benefited from “~$1 per share of non-recurring investment income” boosting results (www.businesswire.com). Such investment gains are not predictable quarter to quarter. A downturn in financial markets could hit the investment income line or capital levels. Lastly, any downgrade of Elevance’s credit ratings (currently strong) could raise borrowing costs (www.elevancehealth.com). So far the balance sheet remains solid, but macroeconomic swings bear keeping in mind.
Open Questions & Outlook Ahead of Q2
As Elevance heads into the Q2 earnings release, a few key questions linger for investors and analysts:
- Are medical cost trends improving? Management signaled that Q1 claims experience was “consistent with expectations” (apnews.com) and that cost actions are taking hold. Investors will look for an update on the benefit expense ratio in Q2 – particularly in Medicaid and Medicare Advantage. Any moderation in utilization or successful cost containment (e.g. through clinical programs or network management) would be a positive sign. Conversely, if the medical loss ratio ticks up unexpectedly, it could raise concerns that 2024’s challenges are not fully behind the company.
- Will Elevance adjust its guidance? After raising full-year EPS guidance in Q1 (www.elevancehealth.com), will the company reaffirm that outlook or tweak it again after Q2? The Q2 report and conference call will be an opportunity for management to update its assumptions. Strong Q2 results could prompt another guidance bump, whereas any hints of renewed pressure (e.g. higher outpatient utilization or pricing shortfall in certain markets) might keep guidance just steady. Also worth watching: management’s commentary on achieving the long-term goal of 12%+ EPS growth by 2027 (www.elevancehealth.com) – are they still on track for that ramp-up?
- Membership and revenue growth dynamics: Q2 is likely to show the ongoing shift in Elevance’s enrollment mix. Medicaid membership may decline further due to eligibility redeterminations (though that headwind should taper off by year-end). Medicare Advantage enrollment might be roughly flat or slightly down if the company has tightened underwriting to protect margins. On the other hand, commercial enrollment (especially fee-based ASO accounts) was a bright spot in Q1 (www.elevancehealth.com) – did that momentum continue into Q2? Any color on the upcoming 2027 Medicare bid season or pricing for 2026 products will also be valuable for forecasting growth. Essentially, investors will want to see that Elevance can offset public program attrition with gains elsewhere (commercial or marketplace plans) to keep top-line growth on track.
- Progress of Carelon & diversification efforts: Elevance’s strategy involves diversifying beyond traditional insurance into healthcare services (Carelon). In Q1, the Carelon segment (comprising pharmacy benefit manager CarelonRx and Carelon Services) grew revenue nearly 8% YoY to $18 billion (www.elevancehealth.com). However, Carelon’s operating profit dipped ~4% as the company invested in expanding risk-based services (www.elevancehealth.com). Investors will be looking in Q2 for signs of margin improvement in Carelon or at least an update on those investments. Can the services segment accelerate growth and profitability in the back half of 2026? Any new partnerships or technology initiatives in Carelon could be a catalyst. This business is key to Elevance’s evolution (and command of the value chain), so watch for management’s commentary on its trajectory.
- Resolution of regulatory uncertainties: Any update on the CMS notice accrual would be significant. If management provides clarity – for example, that negotiations or appeals are progressing, or that no further reserve is needed beyond the $935M taken – it could alleviate an overhang. Conversely, silence or additional accruals in Q2 might signal the issue is still unresolved. Additionally, investors will listen for discussion on the regulatory climate: after CMS’s final 2027 rate decision, are there any other pending rules (such as pharmacy rebate reforms, Medicare Part D changes, or ACA risk pool adjustments) that could impact earnings? How is Elevance positioning itself in Washington D.C. to mitigate policy risk? The political outlook (with an election next year) could influence the longer-term narrative for health insurers, so any insights there will be valuable.
Bottom Line: Elevance Health enters its Q2 earnings announcement on a cautiously optimistic note – the company has navigated recent headwinds by adjusting pricing, cutting costs, and leaning on its diversified model. Investors will be focused on whether those efforts are translating into improved financial performance without new surprises. The stock’s current valuation and capital return profile suggest a lot of bad news is already priced in. If Q2 results confirm stabilizing cost trends and steady execution, it could build confidence that Elevance is back on a growth footing for 2026 and beyond. Conversely, any relapse in medical cost management or unsettling commentary could revive concerns. Keep an eye on the metrics and management’s tone: Elevance’s ability to consistently execute through the healthcare cycle will determine if shares can continue to recover lost ground in the second half of the year.
Sources:
1. Elevance Health Q1 2026 Earnings Press Release (www.elevancehealth.com) (www.elevancehealth.com) 2. Elevance Health Q4 2025 Earnings Press Release (www.elevancehealth.com) (www.elevancehealth.com) 3. Kiplinger Earnings Calendar (Consensus EPS) (www.kiplinger.com) 4. CompaniesMarketCap.com – Elevance Health Valuation Metrics (companiesmarketcap.com) (companiesmarketcap.com) 5. AP News – Medicaid Costs and 2024 Guidance Cut (apnews.com) (apnews.com) 6. Axios – Medicare Advantage Rate News (www.axios.com) (www.axios.com) 7. Elevance 2025 10-K Filing – Debt & Capital Details (app.edgar.tools) (app.edgar.tools) 8. FinViz – Elevance Dividend Yield and Payout (finviz.com) 9. AP News – UnitedHealth & Elevance Commentary (apnews.com)
